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Introduction. The concept of underactive bladder is relatively new. Currently 
there is no generally accepted definition of this pathology. Diagnosis 
depends on urodynamic findings, and symptoms are usually rare and 
intricated with the symptoms of other urinary pathology. 
Matherials and methods. This review examines the current literature on 
underactive bladder regarding pathology, definition, diagnosis, current 
guidelines, and any further potential medical developments.  
Conclusions. Underactive bladder is a poorly understood pathologic 
condition. Only since 2002 has there been any consensus regarding the 
definition. The diagnosis relies only on urodynamics; clinical diagnosis is a 
challenge even for a consultant; and treatment does not seem to alleviate 
much of the suffering. This disease remains underrecognized and 
undertreated. More research is needed to identify less invasive diagnosis 
tools and treatment for this pathology.       
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In 2002, the International Continence Society reviewed 
the existing data and arrived at a definition for underactive 
bladder: ‘a contraction of reduced strength and/or duration, 
resulting in prolonged bladder emptying and/or failure to 
achieve complete bladder emptying within a normal time 
span’. However, the definition for this pathology had been 
evolving over some time. For instance, in 1996 the 
International Continence Society defined underactive 
bladder as failure to induce emptying of at least half of the 
bladder with involuntary recurrent contractions without the 
evidence of straining, urethral obstruction, and detrusor 
sphincter dyssynergia. After the 2002 definition was 
presented (above), in 2010, the society revised the 
definition as a decrease in detrusor contraction and/or 
shortening of the contraction time, resulting in an 
incomplete and/or prolongation of the bladder emptying 
within the normal time frame [1]. 
For years, this condition has been overlooked. Its 
counterpart, the overactive bladder, had received much 
greater research interest, perhaps due to its more intrusive 
symptomatology.  
The pathology has borne many names: impaired 
detrusor contractility, bladder failure, bladder 
decompensation, hypotonic bladder, detrusor areflexia, 
and detrusor failure and detrusor underactivity, although 
some authors suggest the last one represents its own 
category, a point subject to debate [2-4]. 
The diagnosis for this disease relies mostly on 
urodynamic findings. The prevalence increases with age 
and is typically greater in men. Prevalence ranges from 9 
to 28% in men under 50 years old and more than 48% in 
those over 70 years old. In women, the incidence ranges 
from 12 to 45% [5,6]. Yet, no consensus exists for 
threshold urodynamic values for disease categorization. 
Although various papers have proposed different 
thresholds, no widely accepted guidelines currently exist. 
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Discussions 
A comprehensive search of PubMed, Scopus, and other 
databases was conducted using key words like 
"underactive bladder, detrusor underactivity". Review 
articles were selected. Several older papers were included 
for citations and historic interest. Prevalence, etiology, 
diagnosis, and treatment possibilities were searched. The 
purpose of this paper is to highlight the cardinal aspects of 
this pathology.  
Etiology 
The etiology of this disease is wide and may be 
separated into five broad categories: idiopathic - young 
patients with no apparent affections; myogenic - any 
subvesical obstacle and diabetes, autonomic diabetic 
neuropathy [7], Parkinson disease, different types of 
sclerosis, disc hernias [8];  spinal cord injury, spinal 
dysraphism and stenosis; infectious - HIV, herpes zoster, 
herpes simplex and neurosyphilis; and last iatrogenic - 
pelvic surgery, radical prostatectomy, radical hysterectomy 
[9-11]. In diabetes, chronic hyperglycemic status induces a 
series of tissues and organ damages. Microvascular 
involvements in diabetic patients are more common; 
retinopathy, neuropathy, and chronic kidney disease are the 
main complications in diabetes. Autonomic diabetic 
neuropathy develops a series of urological sequelae like 
erectile dysfunction, retrograde ejaculation, and diabetic 
bladder dysfunction. More than half of diabetic patients 
develop diabetic bladder dysfunction, and clinical signs are 
described as a triad, including a bladder sensation decrease, 
bladder capacity increase, and imperfect detrusor 
contractility [12]. Moreover, modifications appear at the 
urothelium level: decreases in E- cadherin levels and 
muscarinic receptor 2 and 3 expressions seem to be lower 
in patients with underactive bladder [13]. 
The most frequent cause is the neurogenic one; actually 
disruption of the efferent neural pathways seems to be one 
of the most frequent types of neural damage. From the 
pathologic point of view, changes in the ultrastructure of 
myocytes and gap junctions inhibit detrusor contraction 
and deposition of collagen between muscle bundle [14,15]. 
Diagnosis 
A proper diagnosis requires some sort of invasive 
method, specifically urodynamic assessment. The 
diagnosis can be difficult because of the overlapping 
symptoms with other pathologies like bladder outlet 
obstruction, benign prostatic hyperplasia, and overactive 
bladder. The condition can be deceptive, sometimes 
presenting with both voiding and storage symptoms. 
Urgency (63.3%), weak stream (61%), straining to void 
(57%), and nocturia (48.1%) may all be present, making it 
difficult to differentiate from other related diseases. In one 
paper, the authors stressed the importance of pressure flow 
investigations, as 12,7% of patients with underactive 
bladder were mistakenly treated with anticholinergics [16]. 
Patients presenting with overactive bladder and 
receiving some form of treatment may change at some 
point in their pathology, and an overstimulated bladder can 
become hypotonic. Moreover, overactive bladder, bladder 
outlet obstruction, and underactive bladder can coexist, 
making it difficult to treat. In diabetes, the first process is 
bladder hypertrophy with increased contractility, which 
leads to polyuria. The second stage is linked with 
hyperglycemic status which leads to the development of 
toxic metabolites which affect normal bladder function and 
promote the detrusor muscle dysfunction. In the end stage, 
both mechanisms will lead to an atonic bladder. Chronic 
hyperglycemic status induces chronic oxidative stress and 
releases reactive oxygen species. This partially explains the 
pathophysiology of diabetic bladder dysfunction, 
especially damaging neuronal fibers, smooth muscles, and 
altering urothelial function [17-19]. Recognized clinical 
risk factors include age, indwelling urinary catheter, 
diabetes, history of urinary retention, and neurologic 
conditions [20-26]. 
Still, many useful tools besides urodynamics are 
available to help recognize this condition. A thorough 
anamnesis from the patient is mandatory in order to 
identify any risk factors for this pathology. A voiding diary 
is useful to determine the severity of the symptoms; a 
neurological exam should also be conducted. The Schaefer 
nomogram or a comparable tool may be used to measure 
obstruction and detrusor contractility [27]. 
Efforts are ongoing to identify and standardize different 
clinical tools that can differentiate this pathology from 
other lower urinary tract diseases. For example, Gammie et 
al. compared normal patients with underactive bladder 
patients: Men with underactive bladder (DU) had 
statistically higher occurrence of decreased/interrupted 
stream (56% versus 30%), hesitancy (51% versus 26%), 
feeling of incomplete bladder emptying (36% versus 22%), 
palpable bladder (14% versus 1.1%), and absent/decreased 
sensation (13% versus 3.0%). Women with DU had higher 
rates of decreased/interrupted stream (29% versus 4.0%), 
hesitancy (28% versus 9.1%), feeling of incomplete 
emptying (28% versus 20%), palpable bladder (3.3% 
versus 1.5%), absent/decreased sensation (4.3%versus 
0.8%), enuresis (12% versus 8.4%), and impaired mobility 
(13% versus 2.8%). On the other hand, when compared to 
those with bladder outlet obstruction, men with 
underactive bladder reported higher rates of sexual 
dysfunction, stress incontinence, palpable bladder, 
enuresis, training to void, and absence of sensation. Better 
results included better stream, hesitancy, and urgency [28]. 
Overlapping their findings with urodynamics should be 
the next logical step. The symptomatology of this disease 
Underactive bladder - an underestimated entity 
 25 
is so undefined that there is need for discrimination tools 
for all the signs and symptoms [29,30]. For instance, 
multiple sclerosis can manifest with obstructive symptoms 
predominantly or diabetes with reduced sensation of 
bladder fullness due to the diabetic neuropathy. 
Urodynamics 
Currently, pressure flow urodynamic testing is the only 
accepted and reliable tool for diagnosing underactive 
bladder. Even this investigation is controversial, for 
example, with respect to the maximum normal value of 
voiding pressure. Moreover, there is no accepted 
urodynamic definition values for underactive bladder. 
Several universally accepted parameters can narrow down 
the list, including a bladder contractility index (BCI) of 
<100 (PdetQmax + 5Qmax), detrusor pressure at max flow 
(PdetQmax) of <30mmH2O and a maximum flow rate 
(Qmax) of <12ml/sec, and a bladder outlet obstruction 
index (BOOI) (PdetQmax – 2Qmax) of <20 and a Qmax of 
<12ml/sec [31,32]. Others use the Watts factor, which is an 
estimate of the power per unit area of the bladder surface 
that is generated by the detrusor. This measure is not 
affected by bladder volume and is therefore not influenced 
by increased outlet resistance. Unfortunately there are no 
standards for its use, and its complexity makes it a 
challenge to use [33,34]. 
Projected isovolumetric pressure - PIP and its 
derivates: bladder contractility index - BCI and detrusor 
coeficient - DECO have the advantage of being much 
easier to use; however, they may overestimate PIP and 
have less test-retest reliability than measuring 
isovolumetric pressures directly [35]. 
Another useful urodynamic investigation is the 
mechanical occlusion of flow. This test can be controlled 
by the patient or if needed by the doctor by compressing 
the urethra. This test tends to underestimate pressure by 20 
cc H2O.  
Unfortunately, its greatest disadvantage is that it cannot 
be applied to patients with sphincter weakness or to elderly 
patients. Compression of the urethra can also be a rather 
painful procedure. We also mention two other measures, 
detrusor contraction speed or detrusor velocity, both of 
which have limited use in general practice [36].  
Treatment options 
Treatment can be classified as behavioral, medical, 
surgical, and experimental/promising. Behavioral 
treatment includes time voiding and double voiding, which 
can reduce the urinary stasis and its subsequent sequelae. 
Intermittent catheterization or catheterization is one of the 
last solutions and greatly affects the life quality of the 
patients and increases the risk of other complications such 
as infection, urethral stricture, urethroragia, and so on.  
Medical treatment, on the other hand, has unfortunately 
shown little or no success. One of the most used classes of 
substances are the parasympathomimetics with their main 
representative bethanechol chloride. This substance is a 
parasympathomimetic choline carbamate that selectively 
stimulates muscarinic receptors with little effect on 
nicotinic receptors. Distigmine bromide, another 
parasympathomimetic, is an acetylcholinesterase inhibitor 
that inhibits the acetylcholinesterase enzyme from 
deactivating acetylcholine, thereby increasing both the 
 
Table 1. A schematic representation of most common urodynamic tests [37]. 
Methods  Advantages  Disadvantages  
 
Bladder contractility index  
 
Easy to use  
 
Not validated in women; cannot 
measure contraction sustainability  BCI = PdetQmax + 5Qmax 
DU = BCI <100 
Watts Factor  Not affected by bladder outlet 
obstruction (BOO); measures 
bladder power  
Complex formula; impractical to use 
clinically; cannot measure contraction 
sustainability; diagnostic thresholds not 
established  
WF = [(pdet + a) (vdet + b) – 
ab]/2π 
Mechanical flow occlusion  Measures isovolumetric contraction 
strength  
Cannot be done in those with sphincter 
weakness or elderly; painful and 
impractical  
Stop test 
Continuous occlusion test 
Maastricht-Hannover nomogram  Quantifies relationship between 
detrusor contractility and BOO  
Not validated in women  
DU ≤25th percentile 
Urodynamic cut-offs  Easy to use  No accepted normal ranges  
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level and duration of action of acetylcholine in 
neuromuscular junctions. Both of them have been used for 
many years and both have produced conflicting results. 
Barendrecht et al in their review concluded that there is 
no evidence for using these drugs in the treatment of 
underactive bladder, taking into account the potential side 
effects which include nausea, vomiting, diarrhea, 
gastrointestinal cramps, bronchospasms, salivation, 
sweating, headache, flushing, visual accommodation 
defect, and the rare but potentially lethal complication of 
cardiac arrest. Moreover, this medication showed 
improvement over the control group only in three of 10 
studies, the remaining seven showing no benefit, and one 
even worsening the symptomatology [38,39]. 
Alpha blockers represent a widespread medication for 
bladder outlet obstruction, currently recommended in the 
European guidelines as first line therapy for this disease. 
Their effect lies more in the bladder neck where the 
concentration of alpha receptors is the highest as compared 
to the overall bladder [40]. 
The use of colinestherase inhibitors distigmine, 
pyridostigmine, and neostigmine are efficient neurologic 
medication and have been supported in the treatment of 
underactive bladder. For example, Sugaya et al, in 
relatively recent paper testing distigmine associated with 
alpha blockers, noticed an improvement in the IPSS score, 
quality of life scores, and post voiding residue. Still this 
type of medication has several annoying side effects, 
including frequent defecation, fecal incontinence, diarrhea, 
frequent urination, and decrease in physical condition [41]. 
Prostaglandin E2, a substance derived from cardiac 
medication, increases detrusor contraction and relaxes the 
urethra. It is administered intravesically but has no 
recommendations for sole use. Severa; studies have 
combined PGE2 with oral bethanecol with promising 
results, but no general recommendations have as yet 
followed [42-44]. 
Acotiamide is an oral agent that regulates the motility 
of the upper gastrointestinal tract in patients with 
abdominal symptoms related to hypomotility and delayed 
gastric emptying. 100 mg dose t.i.d. seems effective for 
patients with underactive bladder. Sugimoto et al have 
emphasized this substance as an alternative to distigmine 
[45]. 
Surgical treatment consists of a wide variety of 
procedures and nerve stimulation techniques ranging from 
sacral electrical stimulation, injections into the external 
sphincter, trans-urethro resection of the prostate, reduction 
cystoplasty, latissimus dorsi detrusor myoplasty, 
transurethral incision of the bladder neck in women, and 
bladder diverticulectomy. 
Some of them, like TUR-P or incision of the bladder neck 
in women and injections of botulinum toxin into the 
external sphincter, are surgical procedures meant to relieve 
the obstruction. Others like reduction cystoplasty, 
latissimus dorsi myoplasty, and bladder diverticulectomy 
have the purpose of eliminating the complications of this 
disease, the aging of the bladder [45,46]. 
Conclusions 
Underactive bladder or any of its synonyms is a poorly 
understood disease with a very difficult diagnosis. Clinical 
diagnosis has limited value and positive diagnosis is based 
only on urodynamics. Even bladder pressure studies have 
limitations, as normative values are missing. No 
standardized efficient treatment exists, so therapy tends to 
be tailored, as some drugs work on some patients, some do 
not. Medical approach has limited use, surgery can relieve 
the pressure only for a short time like TUR-P, or it deals 
with disease complications. Sacral neuromodulation seems 
for now to be the only real efficient treatment. Future 
therapies like gene therapy or stem cells therapy show great 
promise but need to be supported by well-designed 
empirical studies.  
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